Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Waterjel R1 + Waterjel R2 is a two-step, cytokine-containing, milk protein–based topical skin care system designed to prevent and reduce acute radiation dermatitis in patients undergoing radiotherapy, particularly for breast cancer and squamous cell carcinoma of the head and neck.[3][11] R1 is a water-based cooling gel applied shortly after radiation treatment to cool, hydrate, and stabilize skin temperature, while R2 is a soothing, moisturizing lotion with UVA/UVB stabilizers that helps maintain skin hydration, elasticity, and barrier function during and after a radiotherapy course.[3][7][10][11] Both products contain Lactokine (a milk-derived protein complex with cytokine activity), which is proposed to modulate inflammatory responses and support skin repair, and the system has been approved in Europe as a class IIa medical device for prevention of radiation dermatitis and marketed in the United States as Radiaderm Advanced Skincare System.[3][7][11]
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on Waterjel R1 + Waterjel R2.